1-(2-Naphthyl)ethanol is a chiral organic compound with the following structure:
* **Structure:** It consists of a naphthalene ring (two fused benzene rings) with a hydroxyl group (-OH) attached to the first carbon atom of the naphthalene ring and an ethyl group (-CH2CH3) attached to the second carbon atom.
**Why is 1-(2-Naphthyl)ethanol important for research?**
1-(2-Naphthyl)ethanol is not commonly known for being directly important in research. It's likely a compound that researchers may encounter in synthetic chemistry or as a potential intermediate in organic synthesis. However, its importance stems from several factors:
* **Chiral Building Block:** Due to its chiral nature (having a stereogenic center), it can be used as a building block in the synthesis of other chiral molecules. This is particularly relevant in the pharmaceutical industry, where enantiomers (mirror-image forms) of a drug can have different biological effects.
* **Stereochemistry Studies:** It could be used in studies related to understanding and controlling stereochemistry in chemical reactions. Researchers might use it to investigate the influence of chirality on reaction pathways and product formation.
* **Material Science:** It might have potential applications in the synthesis of functional materials with specific properties. For example, its naphthyl group might impart fluorescence or other optical properties to the resulting materials.
**To understand its specific importance, more context is needed:**
* **What specific research area are you interested in?**
* **What is the context of its use?** Is it a starting material, a product, or a reagent?
* **What are the specific properties of 1-(2-Naphthyl)ethanol that are of interest?**
Providing more information about your inquiry would allow for a more specific and relevant response.
ID Source | ID |
---|---|
PubMed CID | 98243 |
SCHEMBL ID | 110360 |
MeSH ID | M0356681 |
Synonym |
---|
2-naphthalenemethanol, .alpha.-methyl-, ( )- |
2-naphthalenemethanol, .alpha.-methyl-, (.+/-.)- |
1-(2-naphthyl)ethanol |
.alpha.-methyl-2-naphthalenemethanol |
nsc92277 |
7228-47-9 |
nsc-92277 |
IDI1_031077 |
alpha-methyl-2-naphthalenemethanol, 98% |
MAYBRIDGE4_000495 |
NCGC00177518-01 |
HMS1522G11 |
N0788 |
alpha-methyl-2-naphthalenemethanol |
2-(1-hydroxyethyl)naphthalene |
AKOS000248910 |
BRD-A66746621-001-01-3 |
1-naphthalen-2-ylethanol |
FT-0639633 |
40295-80-5 |
1-(naphthalen-2-yl)ethan-1-ol |
EN300-51954 |
A825040 |
alpha-methylnaphthalene-2-methanol |
einecs 230-630-3 |
nsc 92277 |
FT-0605556 |
FT-0638712 |
1-(naphthalen-2-yl)ethanol |
SCHEMBL110360 |
(+/-)-1-(2-naphthyl)ethanol |
1-(naphthalene-2-yl)ethanol |
2-(1'-hydroxyethyl)naphthalene |
(rs)-1-(2-naphthyl)ethanol |
2-naphthalenemethanol, .alpha.-methyl- |
methyl 2-naphtylcarbinol |
.beta.-naphthyl methyl carbinol |
mfcd00004111 |
AS-14347 |
AMY41195 |
R10069 |
CS-0186229 |
SY289040 |
alpha -methyl-2-naphthalenemethanol |
Z335245116 |
SY107397 |
SY107316 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |